Home
Events
Jobs
About
Members
Contact Us
Castle Biosciences Announces Pricing of Initial Public Offering
July 25, 2019
by
Website Admin
in
Tweet
Share
Pin it
Previous Story
Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors
Next Story
AgilVax Appoints Dr. Joseph Patti as Chief Executive Officer
Top